Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 5/20 | 0.50 |
| ▸ | ACE | P12821 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042469 | 1.00 | OPRD1 (0.52) | OPRD1OPRM1OPRK1MMP2CTSL | |
| SCHEMBL7211697 | 1.00 | OPRD1 (0.52) | OPRD1OPRM1OPRK1MMP2CTSL | |
| SCHEMBL29590936 | 0.99 | OPRD1 (0.51) | OPRD1OPRM1OPRK1MMP2CTSL | |
| Hydrochloric Acid SCHEMBL30333426 | 0.99 | OPRD1 (0.51) | OPRD1OPRM1OPRK1MMP2CTSL | |
| SCHEMBL30939437 | 0.99 | OPRD1 (0.51) | OPRD1OPRM1OPRK1MMP2CTSL | |
| SCHEMBL29714770 | 0.99 | OPRD1 (0.51) | OPRD1OPRM1OPRK1MMP2CTSL | |
| SCHEMBL21437346 | 0.99 | OPRD1 (0.51) | OPRD1OPRM1OPRK1MMP2CTSL | |
| SCHEMBL30805357 | 0.95 | CTSL (0.51) | OPRD1OPRM1OPRK1MMP2CTSL | |
| SCHEMBL29385523 | 0.95 | CTSL (0.51) | OPRD1OPRM1OPRK1MMP2CTSL | |
| Trifluoroacetic Acid SCHEMBL23629875 | 0.94 | OPRD1 (0.47) | OPRD1OPRM1OPRK1MMP2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748396-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-NECTIN4 ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1 ANTIBODY AND USE THEREOF | Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. (CN) | 2026-05-27 | — | — | EP | claimed |
| EP-4746921-A1 | DRUG CONJUGATES OF IMIDAZOQUINOLINE AMINE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Canwell Biotech Limited (CN) | 2026-05-27 | — | — | EP | claimed |
| CN-122080121-A | Linker and use thereof in ligand drug conjugates | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| EP-4732851-A1 | LINKER, ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR | Fudan University (CN) | 2026-04-29 | — | — | EP | claimed |
| EP-4731673-A1 | NECTIN-4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | Eli Lilly and Company (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260102507-A1 | CAMPTOTHECIN DERIVATIVE FOR TREATING OR PREVENTING CANCER AND ANTIBODY-DRUG CONJUGATE THEREOF | CHENGDU BRILLIANT PHARMACEUTICAL CO LTD (CN) | 2026-04-16 | — | — | US | claimed |
| EP-4725969-A1 | ANTI-HER2 COMPLEMENTARY BISPECIFIC ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. (CN) | 2026-04-15 | — | — | EP | claimed |
| US-6458347-B1 | Drug complex | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2002-10-01 | — | — | US | claimed |
| CN-1073113-C | Camptothecin derivative and preparation method and application thereof | TANABE SEIYAKU CO (JP) | 2001-10-17 | — | — | CN | claimed |
| EP-0781781-B1 | Camptothecin derivatives | TANABE SEIYAKU CO (JP) | 2001-10-10 | — | — | EP | claimed |
| CN-1300733-A | Comptothecin compounds and preparation thereof | TANABE SEIYAKU CO (JP) | 2001-06-27 | — | — | CN | claimed |
| US-5892043-A | MIXTURE WITH POLYSACCHARIDE AND PEPTIDE; ANTITUMOR AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1999-04-06 | — | — | US | claimed |
| EP-0757049-B1 | Camptothecin derivatives | TANABE SEIYAKU CO (JP) | 1999-03-24 | — | — | EP | claimed |
| US-5837673-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1998-11-17 | — | — | US | claimed |
| CN-1158334-A | Camptothecin derivatives | TANABE SEIYAKU CO (JP) | 1997-09-03 | — | — | CN | claimed |
| EP-0781781-A2 | Camptothecin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1997-07-02 | — | — | EP | claimed |
| EP-0757049-A1 | Camptothecin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1997-02-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | CLTB, DCLRE1A, FCGRT | OPRD1 2720/4885OPRM1 2483/4885OPRK1 2885/4885 |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | CHEK1, ATR, MRE11 | OPRD1 2627/4885OPRM1 3393/4885OPRK1 3381/4885 |
| US-20260102507-A1 | CAMPTOTHECIN DERIVATIVE FOR TREATING OR PREVENTING CANCER AND ANTIBODY-DRUG CONJUGATE THEREOF | MALT1, FCGRT, CHN2 | OPRD1 3056/4885OPRM1 933/4885OPRK1 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.